Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Aurobindo Pharma Ltd
Quarter-by-quarter operating performance
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 6,473 | 6,851 | 7,219 | 7,352 | 7,580 | 7,567 | 7,796 | 7,979 | 8,382 | 7,868 | 8,286 | 8,646 | 8,853 |
| Expenses + | 5,477 | 5,702 | 5,846 | 5,753 | 5,920 | 5,949 | 6,230 | 6,401 | 6,622 | 6,265 | 6,608 | 6,873 | 7,103 |
| Operating Profit | 996 | 1,149 | 1,373 | 1,599 | 1,660 | 1,618 | 1,566 | 1,578 | 1,760 | 1,603 | 1,678 | 1,773 | 1,750 |
| OPM % | 15% | 17% | 19% | 22% | 22% | 21% | 20% | 20% | 21% | 20% | 20% | 21% | 20% |
| Other Income + | 135 | 47 | 188 | 163 | 14 | 221 | 136 | 159 | 135 | 107 | 122 | 123 | 117 |
| Interest | 56 | 57 | 68 | 76 | 89 | 111 | 113 | 118 | 115 | 98 | 95 | 93 | 98 |
| Depreciation | 346 | 327 | 418 | 423 | 354 | 404 | 382 | 419 | 444 | 406 | 429 | 465 | 479 |
| Profit before tax | 730 | 812 | 1,076 | 1,262 | 1,230 | 1,324 | 1,207 | 1,200 | 1,335 | 1,207 | 1,276 | 1,339 | 1,291 |
| Tax % | 31% | 30% | 30% | 26% | 26% | 31% | 32% | 30% | 32% | 32% | 34% | 32% | 29% |
| Net Profit + | 506 | 570 | 752 | 940 | 907 | 918 | 817 | 846 | 903 | 824 | 848 | 910 | 921 |
| EPS in Rs | 8.64 | 9.74 | 12.92 | 15.98 | 15.51 | 15.69 | 14.07 | 14.56 | 15.56 | 14.20 | 14.61 | 15.67 | 15.86 |
Financials of Aurobindo Pharma Ltd
Annual income statement trend
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 12,103 | 13,772 | 14,910 | 16,463 | 19,564 | 23,099 | 24,775 | 23,455 | 24,855 | 29,002 | 31,724 | 33,653 |
| Expenses + | 9,524 | 10,579 | 11,469 | 12,691 | 15,612 | 18,249 | 19,497 | 19,060 | 21,148 | 23,176 | 25,173 | 26,807 |
| Operating Profit | 2,579 | 3,193 | 3,441 | 3,772 | 3,952 | 4,849 | 5,278 | 4,396 | 3,707 | 5,826 | 6,551 | 6,846 |
| OPM % | 21% | 23% | 23% | 23% | 20% | 21% | 21% | 19% | 15% | 20% | 21% | 20% |
| Other Income + | 81 | 200 | 115 | 105 | 70 | 166 | 3,195 | 152 | 291 | 366 | 622 | 428 |
| Interest | 160 | 257 | 67 | 78 | 263 | 305 | 74 | 49 | 140 | 290 | 457 | 384 |
| Depreciation | 333 | 392 | 428 | 558 | 668 | 967 | 1,055 | 1,127 | 1,245 | 1,522 | 1,649 | 1,778 |
| Profit before tax | 2,168 | 2,744 | 3,061 | 3,241 | 3,091 | 3,743 | 7,344 | 3,373 | 2,612 | 4,380 | 5,066 | 5,112 |
| Tax % | 28% | 26% | 25% | 25% | 24% | 24% | 27% | 22% | 26% | 28% | 31% | 31% |
| Net Profit + | 1,571 | 2,024 | 2,301 | 2,423 | 2,364 | 2,844 | 5,334 | 2,647 | 1,928 | 3,169 | 3,484 | 3,503 |
| EPS in Rs | 26.98 | 34.61 | 39.29 | 41.36 | 40.36 | 48.56 | 91.05 | 45.20 | 32.90 | 54.15 | 60.02 | 60.34 |
| Dividend Payout % | 8% | 7% | 6% | 6% | 6% | 6% | 4% | 20% | 23% | 8% | 0% | 0% |
Financials of Aurobindo Pharma Ltd
Capital structure and asset base
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 29 | 59 | 59 | 59 | 59 | 59 | 59 | 59 | 59 | 59 | 58 | 58 |
| Reserves | 5,127 | 7,229 | 9,313 | 11,622 | 13,832 | 16,766 | 21,871 | 24,517 | 26,781 | 29,784 | 32,595 | 37,833 |
| Borrowings + | 4,451 | 5,041 | 3,364 | 4,770 | 6,967 | 5,826 | 5,339 | 2,851 | 5,286 | 6,648 | 8,263 | 8,073 |
| Other Liabilities + | 3,303 | 3,568 | 3,464 | 4,492 | 5,414 | 6,113 | 6,147 | 6,211 | 7,379 | 8,227 | 8,566 | 12,538 |
| Total Liabilities | 12,910 | 15,896 | 16,200 | 20,942 | 26,271 | 28,765 | 33,416 | 33,638 | 39,505 | 44,717 | 49,482 | 58,502 |
| Fixed Assets + | 3,706 | 4,180 | 4,834 | 6,521 | 8,475 | 9,396 | 9,374 | 10,532 | 11,024 | 14,493 | 14,794 | 19,611 |
| CWIP | 420 | 848 | 1,458 | 1,583 | 1,668 | 1,986 | 3,062 | 3,747 | 5,390 | 3,869 | 4,900 | 3,009 |
| Investments | 20 | 123 | 246 | 312 | 360 | 555 | 591 | 997 | 543 | 372 | 252 | 1,051 |
| Other Assets + | 8,765 | 10,745 | 9,662 | 12,527 | 15,768 | 16,827 | 20,390 | 18,362 | 22,549 | 25,983 | 29,536 | 34,831 |
| Total Assets | 12,910 | 15,896 | 16,200 | 20,942 | 26,271 | 28,765 | 33,416 | 33,638 | 39,505 | 44,717 | 49,482 | 58,502 |
Financials of Aurobindo Pharma Ltd
Operating, investing and financing cash movement
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 1,237 | 1,420 | 3,279 | 1,955 | 1,651 | 4,381 | 3,329 | 5,016 | 2,387 | 2,435 | 3,925 | 5,526 |
| Cash from Investing Activity + | -1,017 | -1,446 | -1,787 | -1,927 | -2,904 | -1,563 | 597 | -3,211 | -3,971 | -4,242 | -1,866 | -3,459 |
| Cash from Financing Activity + | 93 | 365 | -1,915 | 864 | 1,919 | -1,947 | -1,365 | -2,969 | 1,814 | 800 | 120 | -1,269 |
| Net Cash Flow | 313 | 340 | -424 | 892 | 666 | 871 | 2,561 | -1,164 | 230 | -1,007 | 2,178 | 799 |
| Free Cash Flow | 491 | -146 | 1,594 | 714 | 114 | 2,969 | 1,503 | 2,693 | -323 | -1,067 | 1,408 | 2,468 |
| CFO/OP | 67% | 67% | 118% | 70% | 61% | 106% | 87% | 143% | 84% | 72% | 86% | 107% |
Financials of Aurobindo Pharma Ltd
Working capital efficiency and return ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 107 | 122 | 68 | 68 | 64 | 68 | 52 | 62 | 66 | 61 | 66 | 77 |
| Inventory Days | 239 | 240 | 246 | 317 | 304 | 289 | 333 | 272 | 275 | 284 | 295 | 326 |
| Days Payable | 136 | 146 | 122 | 128 | 107 | 97 | 103 | 97 | 125 | 129 | 117 | 151 |
| Cash Conversion Cycle | 210 | 217 | 191 | 257 | 260 | 260 | 282 | 237 | 216 | 216 | 244 | 252 |
| Working Capital Days | 50 | 44 | 51 | 50 | 25 | 35 | 52 | 84 | 55 | 66 | 49 | 52 |
| ROCE % | 27% | 27% | 25% | 23% | 18% | 19% | 18% | 13% | 9% | 14% | 14% | 13% |